1. Home
  2. MLYS vs UNF Comparison

MLYS vs UNF Comparison

Compare MLYS & UNF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MLYS
  • UNF
  • Stock Information
  • Founded
  • MLYS 2019
  • UNF 1936
  • Country
  • MLYS United States
  • UNF United States
  • Employees
  • MLYS N/A
  • UNF N/A
  • Industry
  • MLYS Biotechnology: Pharmaceutical Preparations
  • UNF Business Services
  • Sector
  • MLYS Health Care
  • UNF Consumer Discretionary
  • Exchange
  • MLYS Nasdaq
  • UNF Nasdaq
  • Market Cap
  • MLYS 2.9B
  • UNF 3.1B
  • IPO Year
  • MLYS 2023
  • UNF N/A
  • Fundamental
  • Price
  • MLYS $40.40
  • UNF $163.09
  • Analyst Decision
  • MLYS Strong Buy
  • UNF Sell
  • Analyst Count
  • MLYS 6
  • UNF 4
  • Target Price
  • MLYS $46.40
  • UNF $174.75
  • AVG Volume (30 Days)
  • MLYS 1.5M
  • UNF 172.0K
  • Earning Date
  • MLYS 11-10-2025
  • UNF 10-22-2025
  • Dividend Yield
  • MLYS N/A
  • UNF 0.87%
  • EPS Growth
  • MLYS N/A
  • UNF 2.70
  • EPS
  • MLYS N/A
  • UNF 7.98
  • Revenue
  • MLYS N/A
  • UNF $2,432,352,000.00
  • Revenue This Year
  • MLYS N/A
  • UNF $3.19
  • Revenue Next Year
  • MLYS N/A
  • UNF $4.10
  • P/E Ratio
  • MLYS N/A
  • UNF $20.20
  • Revenue Growth
  • MLYS N/A
  • UNF 0.20
  • 52 Week Low
  • MLYS $8.24
  • UNF $147.66
  • 52 Week High
  • MLYS $47.65
  • UNF $243.70
  • Technical
  • Relative Strength Index (RSI)
  • MLYS 49.69
  • UNF 56.07
  • Support Level
  • MLYS $36.56
  • UNF $151.51
  • Resistance Level
  • MLYS $47.65
  • UNF $156.91
  • Average True Range (ATR)
  • MLYS 3.45
  • UNF 4.72
  • MACD
  • MLYS -0.00
  • UNF 1.08
  • Stochastic Oscillator
  • MLYS 50.18
  • UNF 95.22

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

About UNF Unifirst Corporation

UniFirst Corp provides workplace uniforms, protective clothing, and other workplace products and services to businesses in the United States, Canada, and Europe. The U.S. and Canadian Rental and Cleaning segment that accounts for the majority of the company engages in sales rents and sells clothing and non-garment items, and offers a cleaning service that delivers clean uniforms when it picks up dirty or contaminated ones. Manufacturing segment designs and manufactures uniforms and non-garment items. Specialty garments rental and cleaning segment provides specialty garments, non-garments, and cleaning services for nuclear and classroom applications. The First Aid segment provides safety supplies and pill packaging. The Corporate segment consists of various associated costs.

Share on Social Networks: